参考文献/References:
[1] 白宇鸽,徐 玲,段学宁,等.中国乳腺癌专病队列研究:临床队列的设计与初步结果[J].中华流行病学杂志,2020,41(12):2046-2052.
[2] Boyle P.Triplenegative breast cancer:Epidemiological considerations and recommendations[J].Ann Oncol,2012,23(6):7-12.
[3] Dawood S.Triplenegative breast cancer: Epidemiology and management options[J].Drugs,2010,3(70):2247-2258.
[4] Milioli H,Tishchenko I,Riveros C,et al.Basallike breast cancer: Molecular profiles clinical features and survival outcomes[J].BMC Med Genomics,2017,10(1):19-22.
[5] 谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP-11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,48(5):617-619,631.
[6] Gao YB,Ji XN.Biological characteristics and treatment of three negative breast cancer[J].Clin Res China,2012,3(25):417-423.
[7] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范[J].中国癌症杂志,2019,29(8):609-680.
[8] Cortazar P,Zhang L,Untch M,et al.Pathological complete response and longterm clinical benefit in breast cancer:The CT neo BC pooled analysis[J].Lancet,2014,11(384):164-172.
[9] Chen CH,Hua BJ.Advantages of traditional Chinese medicine in the treatment of cancer[J].Chinese Journal Inform TCM,2013,11(20):6-7.
[10] 沈 新,马佳佳,徐 阳,等.调肝理肾解毒汤治疗乳腺癌术后骨转移临床研究[J].陕西中医,2019,40(11):1594-1597.
[11] 李 菁,安凌云,张纪平,等.乳腺癌全程教育模式的构建与效果评价[J].中国急救复苏与灾害医学杂志,2012,7(7):647-650.
[12] 国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:221-225.
[13] 邓铁涛.中医证候规范[M].广州:广东科技出版社,1990:78.
[14] 王子健,刘 芬,韩 捷,等.疏肝健脾方联合化疗治疗晚期三阴性乳腺癌临床疗效观察[J].世界中西医结合杂志,2020,15(5):154-157.
[15] 薛文武,谭婷婷.中医辨证治疗乳腺癌疗效及对患者癌症指标的影响研究[J].陕西中医,2018,39(3):338-340.
[16] Emad A,Rakha PD,Maysa E,et al.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109(1):25-32.
[17] 瞿文超,吴雪卿,冯佳梅,等.中药复方对不同分子分型乳腺癌患者无病生存率及总生存率的影响[J].中医药学报,2017,45(6):92-95.
[18] 季亚婕,唐 菁,陈玮黎,等.辅助化疗对乳腺癌患者中医体质的影响及乳癌术后方的调节作用[J].上海中医药大学学报,2016,30(1):11-14.
[19] 盛佳钰,张馨月,李 琼,等.基于肿瘤微环境中TLR4/NF-κB通路的变化探讨乳癌术后方对乳腺癌小鼠肺转移的影响[J].中华中医药学刊,2016,34(12):2864-2867.
[20] Liao MJ,Ye MN,Zhou RJ,et al.Yiqi formula enhances the antitumor effects of erlotinib for treatment of triplenegative breast cancer xenografts[J].Evid Based Complement Alternat Med,2014,12(24):628-712.
[21] 游紫萱,郑晓筱.逍遥蒌贝散对乳腺癌根治术患者外周血T淋巴细胞及引流液炎症指标的影响[J].陕西中医,2021,42(2):183-186.
[22] Arowosegbe M,Amusan O,Adeola S,et al.Kaempferol as a potential PAK4 inhibitor in triple negative breast cancer:Extra precision glide docking and free energy calculation[J].Current Drug Discovery Technologies,2019,16(6):92-95.
[23] Zhu L,Xue L.Kaempferol suppresses proliferation and induces cell cycle arrest, apoptosis and DNA damage in breast cancer cells[J].Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics,2019,27(6):629-634.
[24] Li S,Yan T,Deng R,et al.Low dose of kaempferol suppresses the migration and invasion of triple-negative breast cancer cells by downregulating the activities of Rhoa and Rac1[J].Onco Targets and Therapy,2017,10(1):4809-4819.
[25] Jia LJ,Huang S,Yin XR,et al.Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction[J].Life Sciences,2018,208(1):123-130.
[26] Zhao ZJ,Jin GG,Ge YH,et al.Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways[J].Inflammopharmacology,2019,27(5):1021-1036.
[27] Hu JJ,Zhang YH,Jiang XX,et al.ROS-mediated activation and mitochondrial translocation of camkii contributes to Drp1-dependent mitochondrial fission and apoptosis in triplenegative breast cancer cells by isorhamnetin and chloroquine[J].Journal of Experimental & Clinical Cancer Research,2019,38(1):225.
[28] 汪旭伟,马 沛,王建伟,等.芍药苷对人乳腺癌MCF-7细胞增殖、侵袭和迁移的影响及机制研究[J].广州中医药大学学报,2020,37(4):716-721.
[29] 朱红岩,孙玉国,曲 杰,等.石见穿多糖抑制人胃癌细胞系MGC-803细胞迁移及其机制的初步研究[J].中国医药导报,2012,9(32):5-7.
[30] 宋 凯.黄芪提取物对乳腺癌细胞增殖的抑制作用机制[J].基因组学与应用生物学,2020,39(8):3792-3796.
相似文献/References:
[1]刘 丹,胥 旸,邢晓静.鸦胆子苦醇对三阴性乳腺癌细胞凋亡的影响[J].陕西中医,2021,(4):419.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.003]
LIU Dan,XU Yang,XING XiaoJing.Effects of BRU on apoptosis of triple negative breast cancer cells[J].,2021,(6):419.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.003]
[2]骆小珊,谢 甦,朱曼荆,等.薯蓣丸联合紫杉醇抑制三阴性乳腺癌细胞MDA-MB-231上皮间质转化作用和机制研究[J].陕西中医,2023,(9):1163.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.001]
LUO Xiaoshan,XIE Su,ZHU Manjing,et al.Effect and mechanism of Dioscorea pills combined with paclitaxel on epithelial-mesenchymal transition in triple-negative breast cancer MDA-MB-231 cells[J].,2023,(6):1163.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.001]
[3]王 成,王晓玲,汪旻琦,等.女贞莲桂白芍汤联合常规辅助化疗治疗三阴性乳腺癌术后疗效研究[J].陕西中医,2023,(12):1735.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.015]
WANG Cheng,WANG Xiaoling,WANG Minqi,et al.Effects of Nvzhen Liangui Baishao decoction combined with routine adjuvant chemotherapy in the treatment of patients with triple negative breast cancer after surgery[J].,2023,(6):1735.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.015]